Samie Mohammad Ali, Xu Haoxing
Department of Molecular, Cellular, and Developmental Biology, University of Michigan, Ann Arbor, MI 48109.
J Lipid Res. 2014 Jun;55(6):995-1009. doi: 10.1194/jlr.R046896. Epub 2014 Mar 25.
Lysosomes are acidic compartments in mammalian cells that are primarily responsible for the breakdown of endocytic and autophagic substrates such as membranes, proteins, and lipids into their basic building blocks. Lysosomal storage diseases (LSDs) are a group of metabolic disorders caused by genetic mutations in lysosomal hydrolases required for catabolic degradation, mutations in lysosomal membrane proteins important for catabolite export or membrane trafficking, or mutations in nonlysosomal proteins indirectly affecting these lysosomal functions. A hallmark feature of LSDs is the primary and secondary excessive accumulation of undigested lipids in the lysosome, which causes lysosomal dysfunction and cell death, and subsequently pathological symptoms in various tissues and organs. There are more than 60 types of LSDs, but an effective therapeutic strategy is still lacking for most of them. Several recent in vitro and in vivo studies suggest that induction of lysosomal exocytosis could effectively reduce the accumulation of the storage materials. Meanwhile, the molecular machinery and regulatory mechanisms for lysosomal exocytosis are beginning to be revealed. In this paper, we first discuss these recent developments with the focus on the functional interactions between lipid storage and lysosomal exocytosis. We then discuss whether lysosomal exocytosis can be manipulated to correct lysosomal and cellular dysfunction caused by excessive lipid storage, providing a potentially general therapeutic approach for LSDs.
溶酶体是哺乳动物细胞内的酸性区室,主要负责将诸如膜、蛋白质和脂质等内吞和自噬底物分解为其基本组成成分。溶酶体贮积症(LSDs)是一组代谢紊乱疾病,由分解代谢所需的溶酶体水解酶基因突变、对分解代谢产物输出或膜运输很重要的溶酶体膜蛋白基因突变,或间接影响这些溶酶体功能的非溶酶体蛋白基因突变引起。LSDs的一个标志性特征是溶酶体内未消化脂质的原发性和继发性过度积累,这会导致溶酶体功能障碍和细胞死亡,进而在各种组织和器官中引发病理症状。LSDs有60多种类型,但大多数类型仍缺乏有效的治疗策略。最近的一些体外和体内研究表明,诱导溶酶体胞吐作用可以有效减少贮积物质的积累。与此同时,溶酶体胞吐作用的分子机制和调控机制也开始被揭示。在本文中,我们首先讨论这些最新进展,重点关注脂质贮积与溶酶体胞吐作用之间的功能相互作用。然后,我们讨论是否可以通过操纵溶酶体胞吐作用来纠正由过度脂质贮积引起的溶酶体和细胞功能障碍,从而为LSDs提供一种潜在的通用治疗方法。